Cargando…
Approach to the Triple Negative Breast Cancer in New Drugs Area
Triple negative breast cancers (TNBCs) are associated with aggressive course, higher rates of visceral and central nervous system metastases and lower survival rate than hormone receptor positive. Once metastasis has occurred, a median survival was approximately one year. Currently, chemotherapy in...
Autor principal: | Mirzania, Mehrzad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888149/ https://www.ncbi.nlm.nih.gov/pubmed/27252813 |
Ejemplares similares
-
Treatment Outcomes and Clinicopathologic Characteristics of Triple-Negative Breast Cancer: A Report from Cancer Institute of Iran
por: Mirzania, Mehrzad, et al.
Publicado: (2017) -
Drug Repurposing for Triple-Negative Breast Cancer
por: Ávalos-Moreno, Marta, et al.
Publicado: (2020) -
Repurposing of drugs for triple negative breast cancer: an overview
por: Spini, Andrea, et al.
Publicado: (2020) -
Investigational Drug Treatments for Triple-Negative Breast Cancer
por: Damaskos, Christos, et al.
Publicado: (2021) -
Current approaches in treatment of triple-negative breast cancer
por: Wahba, Hanan Ahmed, et al.
Publicado: (2015)